Evidence map›Paper›PMID 41430443›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Blood biomarkers of response to concomitant intratympanic and systemic corticosteroids treatment for idiopathic sudden sensorineural hearing loss.

Giancarlo Tirelli, Ludovica Costariol, Federico Cavallo-Ronchi, Egidio Sia, Simone Zucchini, Paolo Boscolo-Rizzo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Regarding "Blood biomarkers of response to concomitant intratympanic and systemic corticosteroids treatment for idiopathic sudden sensorineural hearing loss".European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Giancarlo TirelliDepartment of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Strada di Fiume 447, Trieste, 34149, Italy.
Ludovica CostariolDepartment of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Strada di Fiume 447, Trieste, 34149, Italy.
Federico Cavallo-RonchiDepartment of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Strada di Fiume 447, Trieste, 34149, Italy.
Egidio SiaDepartment of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Strada di Fiume 447, Trieste, 34149, Italy.
Simone ZucchiniDepartment of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Strada di Fiume 447, Trieste, 34149, Italy.
Paolo Boscolo-RizzoDepartment of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Strada di Fiume 447, Trieste, 34149, Italy. paolo.boscolorizzo@units.it.ORCID http://orcid.org/0000-0002-4635-7959

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the prognostic value of hematological inflammatory biomarkers in predicting hearing recovery in patients with idiopathic sudden sensorineural hearing loss (ISSNHL) treated with combined systemic and intratympanic corticosteroids.

methodsThis retrospective study included 125 patients diagnosed with ISSNHL between 2012 and 2021 who received both oral prednisone and intratympanic methylprednisolone. Clinical data and pre-treatment blood samples were collected. Inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were calculated. Hearing outcomes were classified as complete, partial, or no recovery based on pure tone average (PTA) thresholds. Univariate and multivariable logistic regression analyses were performed to identify predictors of recovery.

resultsOf the 125 patients, 33 (26.4%) had no recovery, 50 (40.0%) partial recovery, and 42 (33.6%) complete recovery. Dizziness, current smoking, delayed treatment initiation (> 7 days), elevated triglycerides (≥ 98 mg/dL), and high PLR (≥ 142) were independently associated with a lower probability of hearing recovery. A higher LMR (≥ 3.0) showed a positive trend but did not reach statistical significance in adjusted models.

conclusionsIn patients with ISSNHL treated with dual-route corticosteroids, several clinical and hematologic factors, particularly elevated PLR and delayed treatment, are independently associated with reduced odds of hearing recovery. Inflammatory blood markers may serve as accessible prognostic tools to support early risk stratification.

Indexed as

GlucocorticoidsHearing Loss, SensorineuralHearing Loss, SuddenMethylprednisolonePrednisoneAdultAgedBiomarkersDrug Therapy, CombinationFemaleHumansInjection, IntratympanicMaleMiddle AgedPrognosisRetrospective StudiesBiomarkersGlucocorticoidsMethylprednisolonePrednisoneCorticosteroid therapyHearing recoveryIdiopathic sudden sensorineural hearing lossInflammatory biomarkersIntratympanic injectionPlatelet-to-lymphocyte ratio

Identifiers

PMID41430443
PMCPMC13053341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.